Results of the OPARATIC trial: A phase I dose escalation study of olaparib in combination with temozolomide (TMZ) in patients with relapsed glioblastoma (GBM).

被引：25

作者：

Halford, Sarah E. R.

Cruickshank, Garth

Dunn, Laurence

Erridge, Sara

Godfrey, Lisa

Herbert, Christopher

Jefferies, Sarah

Lopez, Juanita Suzanne

McBain, Catherine

Pittman, Marc

Sleigh, Rebecca

Watts, Colin

Webster-Smith, Mark F.

Chalmers, Anthony J.

机构：

[1] Canc Res UK, Ctr Drug Dev, London, England

[2] Univ Hosp Birmingham NHS Fdn Trust, Birmingham, W Midlands, England

[3] Greater Glasgow & Clyde Hlth Board, Glasgow, Scotland

[4] NHS Lothian, Edinburgh, Scotland

[5] Canc Res UK, London, England

[6] Univ Hosp Bristol NHS Fdn Trust, Bristol, Avon, England

[7] Cambridge Univ Hosp, Cambridge, England

[8] Royal Marsden NHS Fdn Trust, London, England

[9] Christie Hosp NHS Fdn Trust, Manchester, Lancs, England

[10] LGC Grp, Cambridge, England

[11] Univ Cambridge, Cambridge, England

[12] Beatson Canc Ctr, Glasgow, Scotland

来源：

关键词：

D O I：

10.1200/JCO.2017.35.15_suppl.2022

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

2022

引用

页数：5